Searched for
MANKIND PHARMA EMPAGLIFLOZIN
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of more than 27%After being relentless sellers for a large part of the calendar year 2025, FPI numbers for October have turned positive. This is the second...- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of more than 25%The markets have a big element of probability. The way things have panned out in the past few weeks, it is very likely that the bulls will ...
- Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COOEris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...
- Generic versions of key diabetic drug in market double in a monthPost patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and player...
- As Empagliflozin goes off patent, 71 copies of the key diabetes drug roll out in a monthFollowing the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies ...
- New affordable diabetes drug Empagliflozin launched in IndiaSeveral domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices follo...
- Indian pharma cos to launch cheaper diabetes medicine at 90% lower price soonDomestic drug companies in India are preparing to launch affordable generics of the diabetes drug Empagliflozin after the expiry of Boehrin...
Load More